QDEL HealthcareBeta data

QuidelOrtho Corporation

$14.09+0.43%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 966.2M USD
Enterprise value: 3.9B USD
Full-time employees: 6,500

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.39 vs a peer median of 2.59) and more debt relative to equity (1.73× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.39 vs peers 2.59) and more debt vs equity (1.73× vs peers 0.22×)

Ranks #932 of 1,157 healthcare companies (bottom 20%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 87% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 87% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), QuidelOrtho looks cheaper than 87% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, QuidelOrtho looks cheaper than 87% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
QuidelOrtho reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

33/ 100

Oct 5 34 → Nov 4 33 (-1)

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

64/100

Moderate

3/3 inputs reported · High confidence

Why

Stronger than most peers on:

▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-109.5%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield12.4%

Yahoo Finance · trailing 12 monthsReported value50% base weight · Z-score 2.08Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-21.9%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield184.4%

Yahoo FinanceOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

19/100

Weak

2/3 inputs reported · Partial data

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth-5.8%

Yahoo Finance · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score -1.39Sector median: 0.0584 · MAD: 0.0840

Revenue growth-1.9%

Yahoo Finance · fiscal year to Dec 2025Reported value33% base weight · Z-score -0.82Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

39/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ ROIC
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin2.0%

Yahoo Finance · fiscal year to Dec 2025Reported value33% base weight · Z-score -0.41Sector median: 0.0706 · MAD: 0.1217

Return on assets0.4%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -0.24Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-0.9%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -0.56Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin44.9%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-45.9%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.68

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.15Sector median: 0.6250 · MAD: 0.3380

Current ratio1.39×

Yahoo FinanceReported value33% base weight · Z-score -0.87Sector median: 2.5860 · MAD: 1.3850

Debt / equity1.73×

Yahoo FinanceReported value33% base weight · Z-score -7.41Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about QuidelOrtho

Is QuidelOrtho getting weaker?: Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is unchanged at 33/100 since Oct 28, 2026.
How is QuidelOrtho valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 64/100 against 1,393 healthcare peers. EBITDA yield 12.4% vs a peer median of 4.0% (stronger than 87% of peers).EBITDA yield 12.4% vs peers 4.0% (stronger than 87% of peers). Earnings yield -109.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -109.5% vs peers 1.5% (weaker than 100% of peers).
Is QuidelOrtho growing?: More slowly than most of its peers. Growth scores 19/100 against 1,393 healthcare peers. 3-year revenue growth -5.8% vs a peer median of 5.8% (weaker than 83% of peers).3-year revenue growth -5.8% vs peers 5.8% (weaker than 83% of peers).
How profitable is QuidelOrtho?: Less profitable than most of its peers. Profitability scores 39/100 against 1,393 healthcare peers. Return on invested capital -0.9% vs a peer median of 4.7% (weaker than 66% of peers).Return on invested capital -0.9% vs peers 4.7% (weaker than 66% of peers).
How risky is QuidelOrtho?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 1.73× vs a peer median of 0.22× (weaker than 88% of peers).Debt / equity 1.73× vs peers 0.22× (weaker than 88% of peers). A relative measure, not a bankruptcy probability.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.

QDEL price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: higher risk than most peers: less short-term liquidity (current ratio 1.39 vs a peer median of 2.59) and more debt relative to equity (1.73× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.39 vs peers 2.59) and more debt vs equity (1.73× vs peers 0.22×)

Ranks #932 of 1,157 healthcare companies (bottom 20%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 87% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 87% of peers on operating cash profit, but only 0% on earnings.

Relative to its operating cash profit (EBITDA), QuidelOrtho looks cheaper than 87% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, QuidelOrtho looks cheaper than 87% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

QuidelOrtho reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about QuidelOrtho

Is QuidelOrtho getting weaker?

Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is unchanged at 33/100 since Oct 28, 2026.

How is QuidelOrtho valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 64/100 against 1,393 healthcare peers. EBITDA yield 12.4% vs a peer median of 4.0% (stronger than 87% of peers).EBITDA yield 12.4% vs peers 4.0% (stronger than 87% of peers). Earnings yield -109.5% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -109.5% vs peers 1.5% (weaker than 100% of peers).

Is QuidelOrtho growing?

More slowly than most of its peers. Growth scores 19/100 against 1,393 healthcare peers. 3-year revenue growth -5.8% vs a peer median of 5.8% (weaker than 83% of peers).3-year revenue growth -5.8% vs peers 5.8% (weaker than 83% of peers).

How profitable is QuidelOrtho?

Less profitable than most of its peers. Profitability scores 39/100 against 1,393 healthcare peers. Return on invested capital -0.9% vs a peer median of 4.7% (weaker than 66% of peers).Return on invested capital -0.9% vs peers 4.7% (weaker than 66% of peers).

How risky is QuidelOrtho?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 1.73× vs a peer median of 0.22× (weaker than 88% of peers).Debt / equity 1.73× vs peers 0.22× (weaker than 88% of peers). A relative measure, not a bankruptcy probability.